A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Avanafil

Phosphodiesterase 5 Inhibitor class · 1 generic manufacturer · 3 ANDAs filed at FDA.

First FDA approval2024-06-14
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$42.14/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$42.14
Across all dosage forms in distribution.
Highest NADAC
$42.14
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Avanafil used for?

Avanafil is a Phosphodiesterase 5 Inhibitor medication tracked in Medicare Part D.

Is there a generic for Avanafil?

Yes. 3 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Avanafil?

Across 329 Part D plans, Avanafil averages $42.14/unit (NADAC). Lowest available: $42.14/unit. Highest in distribution: $42.14/unit.

Is Avanafil on the FDA shortage list?

No. Avanafil is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Phosphodiesterase 5 Inhibitor3 alternatives in D1
01
Sildenafil
Brand: Revatio
$0.053Lowest NADAC
25Generic mfrs
$66.0MCY24 Part D spend
Compare →
02
Tadalafil
Brand: ADCIRCA
$0.104Lowest NADAC
28Generic mfrs
$161.4MCY24 Part D spend
Compare →
03
Vardenafil
Phosphodiesterase 5 Inhibitor
$2.23Lowest NADAC
5Generic mfrs
$642,093CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.